AIMS : Studies on adherence and persistence with non-vitamin K oral anticoagulant (NOAC) treatment have relied on data from the early years of NOAC availability. We aimed to study long-term adherence and persistence with NOACs and their association with stroke risk. METHODS AND RESULTS : From the Stockholm Healthcare database, we included 21 028 atrial fibrillation patients claiming a first NOAC prescription from July 2011 until October 2018, with more than 1000 patients having more than 5 years of follow-up (median: 2.0, interquartile range: 1.0-3.2). Persistence rates, defined as continuing to claim NOAC prescriptions within a 90-day gap, decreased to 70% at the end of follow-up. However, 85% of the patients were treated at the end of the...
IntroductionTreatment adherence and persistence impact the effectiveness of edoxaban for the prevent...
This study examined characteristics and treatment persistence among patients prescribed oral anticoa...
Aim. To assess adherence to new oral anticoagulants (NOAC) or warfarin therapy and to study the fact...
AIMS : Studies on adherence and persistence with non-vitamin K oral anticoagulant (NOAC) treatment h...
BackgroundSince non-vitamin K antagonist oral anticoagulants (NOACs) do not require coagulation moni...
Background Non-vitamin K antagonist oral anticoagulants (NOAC) have superior safety and comparable e...
Background: A high degree of adherence to direct oral anticoagulants is essential for reducing the r...
Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K ant...
Aims To assess persistence and adherence to non-vitamin K antagonist oral anticoagulant (NOAC) treat...
Background Despite simpler regimens than vitamin K antagonists (VKAs) for stroke prevention in atria...
Aims Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial...
Aims: Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atria...
Background: Oral anticoagulant therapy (OAT) potently prevents strokes in patients with atrial fib...
We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral...
Sebastian Luger,1 Carina Hohmann,2 Daniela Niemann,1 Peter Kraft,3 Ignaz Gunreben,3 Tobias Neumann-H...
IntroductionTreatment adherence and persistence impact the effectiveness of edoxaban for the prevent...
This study examined characteristics and treatment persistence among patients prescribed oral anticoa...
Aim. To assess adherence to new oral anticoagulants (NOAC) or warfarin therapy and to study the fact...
AIMS : Studies on adherence and persistence with non-vitamin K oral anticoagulant (NOAC) treatment h...
BackgroundSince non-vitamin K antagonist oral anticoagulants (NOACs) do not require coagulation moni...
Background Non-vitamin K antagonist oral anticoagulants (NOAC) have superior safety and comparable e...
Background: A high degree of adherence to direct oral anticoagulants is essential for reducing the r...
Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K ant...
Aims To assess persistence and adherence to non-vitamin K antagonist oral anticoagulant (NOAC) treat...
Background Despite simpler regimens than vitamin K antagonists (VKAs) for stroke prevention in atria...
Aims Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial...
Aims: Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atria...
Background: Oral anticoagulant therapy (OAT) potently prevents strokes in patients with atrial fib...
We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral...
Sebastian Luger,1 Carina Hohmann,2 Daniela Niemann,1 Peter Kraft,3 Ignaz Gunreben,3 Tobias Neumann-H...
IntroductionTreatment adherence and persistence impact the effectiveness of edoxaban for the prevent...
This study examined characteristics and treatment persistence among patients prescribed oral anticoa...
Aim. To assess adherence to new oral anticoagulants (NOAC) or warfarin therapy and to study the fact...